-

IFPMA: Pharmaceutical Industry Expresses Deep Disappointment With Decision on Waiving Intellectual Property Rights Adopted at the World Trade Organization Ministerial Conference

  • IFPMA, the body representing biopharmaceutical companies in Geneva, expresses deep disappointment with the decision taken to adopt a TRIPS waiver, despite intellectual property (IP) not being a barrier to vaccine scale-up and wide acknowledgment of vaccines surplus.
  • IP has enabled the rapid research and development of several effective vaccines against COVID-19 and underpinned the more than 380 voluntary partnerships; while trade barriers have severely undermined collective efforts to deliver vaccines to those who need them most.
  • Industry warns that such an “empty shell” and fact-free decision can have severe consequences on innovation and global health security.

GENEVA--(BUSINESS WIRE)--Today’s decision at the World Trade Organization (WTO) Ministerial Conference (MC12) to endorse a TRIPS waiver for COVID-19 vaccines sends the wrong message to those carrying out research and development and innovating. It incorrectly points to intellectual property (IP) as a barrier to the pandemic response rather than an enabler bringing healthcare solutions, safely and quickly to patients.

IP has supported the fastest development and scale-up of safe and effective vaccines in history, with 13.9 billion COVID-19 vaccines produced to date. The IP framework has provided the basis for more than 380 voluntary partnerships for COVID-19 vaccines to be set up in record time, 88% of which involve technology transfer1.

Today’s decision sends a dangerous signal not only to the pharmaceutical industry but to all innovative sectors. Dismantling the very framework that has brought solutions to tackle COVID-19 and facilitated the unprecedented number of partnerships, voluntary licensing, and knowledge-sharing taking place during this pandemic can have ripple effects for the future.

Thomas Cueni, IFPMA Director-General, said: “The conversations on an intellectual property waiver have been challenging from the beginning, with disregard to evidence and facts. The decision is a disservice to the scientists that left no stone unturned and undermines manufacturing partnerships on every continent. The single biggest factor affecting vaccine scarcity is not intellectual property, but trade. This has not been fully addressed by the World Trade Organization”.

About IFPMA

IFPMA (https://www.ifpma.org/) represents the research-based pharmaceutical companies and associations across the globe. The research-based pharmaceutical industry’s 2 million employees discover, develop, and deliver medicines and vaccines that improve the life of patients worldwide. Based in Geneva, IFPMA has official relations with the United Nations and contributes industry expertise to help the global health community find solutions that improve global health.

1 https://www.ifpma.org/resource-centre/research-based-biopharmaceutical-industry-on-the-trips-waiver-discussions-at-wto-ministerial-conference-mc12

Contacts

For further information, please contact
Abigail Jones, a.jones@ifpma.org, +32 475 41 09 76
Ana-Maria Nia, am.nia@ifpma.org, +41 79 585 92 97

Industry:

IFPMA

Details
Headquarters: Geneva, Switzerland
Website: www.ifpma.org
CEO: Thomas Cueni
Employees: 50
Organization: NON
Release Versions
English

Contacts

For further information, please contact
Abigail Jones, a.jones@ifpma.org, +32 475 41 09 76
Ana-Maria Nia, am.nia@ifpma.org, +41 79 585 92 97

More News From IFPMA

Ahead of UN General Assembly, pharmaceutical industry underscores need for pandemic preparedness plans to support innovation and equity

GENEVA--(BUSINESS WIRE)--Ahead of discussions at the United Nations General Assembly (UNGA78), the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) has warned that current pandemic preparedness plans should not undermine what worked well in response to COVID-19 and must support both “innovation and equity.” IFPMA has called for current plans to be strengthened to support the development of vaccines and treatments that will be needed for the next pandemic, alongs...

Biotechs, Developing Countries Vaccine Manufacturers and Pharma Unite Behind a Proposal to G20 and G7 Offering a Practical Solution for Better Access to Vaccines for Future Pandemics

PUNE, India--(BUSINESS WIRE)--The Biotechnology Innovation Organization (BIO), Developing Countries Vaccine Manufacturers’ Network (DCVMN) and the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) have been key players in the historic effort to scale up the manufacturing of COVID-19 vaccines. Today, the three trade bodies representing vaccines innovators and manufacturers who have acquired unique expertise and have worked closely to bring solutions to the COVID-1...

Pharma Proposes to Work with G7 and G20 on a Joint Solution for Better Access to Vaccines and Treatments Around the World for Future Pandemics

GENEVA & BERLIN--(BUSINESS WIRE)--The biopharmaceutical industry launched today the “Berlin Declaration – biopharmaceutical industry vision for equitable access in pandemics” and presents global leaders with a proposal that could help ensure the supply of pandemic vaccines, treatments and diagnostics are delivered as early as possible in future pandemics to those who need them most. The industry, which developed COVID-19 vaccines and treatments at record speed and in historic quantities, propos...
Back to Newsroom